• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Vaxxas Pty. Ltd.

Headquarters: Brisbane, Australia
Website: http://www.vaxxas.com
Year Founded: 2011
Status: Private

BioCentury | Jun 6, 2023
Management Tracks

Jin promoted to CEO at Ensem

Plus: Pedranti named CEO at Visgenx, and updates from Altoida, Vaxxas, Variant, Immodulon and Google Ventures
Read More
BioCentury | Dec 6, 2022
Product Development

Dec. 5 Quick Takes: Nkarta reports 70% complete response

Plus: Verve falls on clinical hold and updates from J&J, Affinia, TherapeuticsMD, Biogen and more
Read More
BioCentury | Dec 1, 2022
Management Tracks

Lee to take the helm at SK Biopharmaceuticals

Plus: Amgen vet Tagari to join insitro as CSO, and updates from Haystack, Vaxxas, Akili and more
Read More
BioCentury | Apr 21, 2022
Management Tracks

Romanelli rejoins Merck to lead Human Health International 

Plus: SIB’s Durinx joins VIB, and updates from Orion, American Cancer Society, Ambys and more
Read More
BioCentury | Apr 14, 2022
Management Tracks

Murphy resigns from MaxCyte

Plus AbbVie’s Severino becomes CEO-partner at Flagship, and updates from Ikena, Fusion, Nimbus and more
Read More
BioCentury | Oct 29, 2021
Discovery & Translation

Omics-based target identification in UK Biobank and COVID-19 cohorts 

Plus: technologies from Harvard, Texas A&M, Disney lab and more
Read More
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

Read More
BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

BioCentury’s roundup of preclinical news
Read More
BioCentury | Feb 16, 2015
Financial News

Vaxxas completes venture financing

Read More
BioCentury | Feb 10, 2015
Financial News

Vaxxas raises $20M in B round

Read More
Items per page:
1 - 10 of 15